Compendia Transparency Document

New Off-Label Uses

Monograph Off-Label Use Proposed Date Participating Panel Member(s) Strength of Recommendation Level of Evidence Off-Label Use Vote Record Panel Member Conflict of Interest Statement
Goserelin Prevention of early menopause during chemotherapy for early stage hormone receptor negative breast cancer 2015.03Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
EquivocalBFor the Off-Label Use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Cisplatin Breast cancer (triple-negative) 2015.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP
Equivocal BFor the Off-Label Use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest
Cisplatin Penile cancer 2015.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Nick Link, PharmD, BCOP

Mark Holdsworth, PharmD
EquivocalBFor the Off-Label Use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Idarubicin AML (Pediatric), relapsed/refractory 2015.04 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Mark Holdsworth, PharmD

Heidi Trinkman, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Strong (for off-label use) AFor the Off-Label Use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Idarubicin AML (Pediatric), newly diagnosed 2015.04Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Mark Holdsworth, PharmD

Heidi Trinkman, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Equivocal B For the Off-Label Use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Topotecan Primary CNS lymphoma, relapsed/refractory 2015.06Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

Equivocal C For the Off-Label Use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Nivolumab Melanoma, unresectable or metastatic (without BRAF mutation), first-line, single-agent therapy 2015.07Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS
Strong A For the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Palbociclib Breast cancer, advanced (second-line endocrine-based therapy) 2015.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link. PharmD, BCOP

Strong A For the Off-Label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Fulvestrant Breast cancer, advanced (second-line endocrine-based combination therapy) 2015.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link. PharmD, BCOP

Strong A For the Off-Label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CabozantinibRenal cell cancer, clear cell (advanced)2015.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Strong A For the Off-Label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Nivolumab Renal cell cancer, clear cell (advanced) 2015.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Strong A For the off-label use: 4 of 5 No conflict of interest

No conflict of interest

Conflict of interest

No conflict of interest

No conflict of interest

GoserelinBreast cancer, advanced (second-line endocrine-based combination therapy [with palbociclib and fulvestrant] in pre- or peri-menopausal women) 2015.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link. PharmD, BCOP

Strong A For the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Ipilimumab Melanoma, unresectable or metastatic, first-line combination therapy 2015.11Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link. PharmD, BCOP

Strong A For the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Trabectedin Ovarian cancer, refractory (platinum-sensitive)2016.02Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

DocetaxelProstate cancer, metastatic, hormone-sensitive2016.03Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

DefibrotideHepatic sinusoidal obstruction syndrome, prevention (pediatrics)2016.04Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Heidi Trinkman, PharmD

Mark Holdsworth, PharmD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

VemurafenibErdheim-Chester disease, refractory (with BRAF V600E mutation)2016.05Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

VemurafenibNon-small cell lung cancer, refractory (with BRAF V600 mutation)2016.05Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

NivolumabHead and neck cancer, squamous cell (recurrent or metastatic)2016.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AxitinibThyroid cancer (advanced, differentiated)2016.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Mark Holdsworth, PharmD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CarfilzomibWaldenström macroglobulinemia2016.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RegorafenibHepatocellular cancer (intermediate or advanced)2016.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Mark Holdsworth, PharmD

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

PembrolizumabMerkel cell carcinoma (advanced)2016.08Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

DabrafenibNon-small cell lung cancer, metastatic, relapsed or refractory (with BRAF V660E mutation)2016.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

TrametinibNon-small cell lung cancer, metastatic, relapsed or refractory (with BRAF V660E mutation)2016.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

NivolumabSmall cell lung cancer (progressive)2016.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

MitomycinVulvar cancer, advanced2016.11Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CarboplatinAnal cancer2016.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalCFor the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CarboplatinGastric cancer2016.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CarboplatinThyroid Cancer2016.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalB, GFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CarboplatinWilms Tumor2016.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Mark Holdsworth, PharmD

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

FluorouracilVulvar cancer, advanced2016.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabMalignant pleural mesothelioma (unresectable)2016.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabHereditary hemorrhagic telangiectasia2016.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Nick Link, PharmD, BCOP

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

TemsirolimusEndometrial cancer (locally advanced, recurrent and/or metastatic)2017.02Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

PembrolizumabUrothelial carcinoma (advanced)2017.02Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

SargramostimNeuroblastoma, high-risk (pediatrics)2017.03Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Heidi Trinkman, PharmD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

IsotretinoinNeuroblastoma, high-risk (pediatrics)2017.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly KIntzel, PharmD, BCOP, BCPS

Heidi Trinkman, PharmD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

IpilimumabSmall cell lung cancer (progressive)2017.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

TocilizumabCytokine release syndrome (due to BiTE therapy), severe or life-threatening2017.04 (modified 2017.09)Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Heidi Trinkman, PharmD

Omer Koc, MD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CapecitabinePancreatic cancer (adjuvant therapy)2017.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

GemcitabinePancreatic cancer (adjuvant therapy)2017.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CapecitabineAnal carcinoma2017.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Antithymocyte globulin (rabbit;Thymoglobulin)Chronic graft-versus-host disease (prevention)2017.05Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongA, GFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

OlaparibBreast cancer, metastatic, HER2-negative, BRCA-mutated2017.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AbirateroneProstate cancer, metastatic or high-risk locally advanced, castration-sensitive2017.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RituximabMyasthenia gravis (refractory)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

Heidi Trinkman, PharmD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RituximabNeuromyelitis optica (relapse prevention)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RituximabPemphigus vulgaris (newly diagnosed)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

Heidi Trinkman, PharmD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CapecitabineBreast cancer (adjuvant therapy)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CapecitabineHepatobiliary cancer (adjuvant therapy)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabGliomas (recurrent or progressive (pediatrics)2017.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Omer Koc, MD

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabMedulloblastoma (relapsed or refractory)2017.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Nick Link, PharmD, BCOP

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabSolid tumors, refractory (pediatrics)2017.10Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Corey Carter, MD

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

LenvatinibHepatocellular carcinoma (advanced)2017.11 (updated; see 2018.03)Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

DurvalumabNon-small cell lung cancer (unresectable, locally advanced)2017.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

FluorouracilGlaucoma surgery (adjunctive therapy)2017.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AlemtuzumabAplastic anemia, refractory2017.11Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Mark Holdsworth, PharmD

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AlemtuzumabHemophagocytic lymphohistiocytosis, refractory2017.11Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Mark Holdsworth, PharmD

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Irinotecan (conventional)Small cell lung cancer (limited stage)2017.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Omer Koc, MD

Corey Carter, MD

Nick Link, PharmD, BCOP

EquivocalB, GFor the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

BevacizumabDiabetic macular edema2017.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

StrongA, GFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Irinotecan (conventional)Unknown primary adenocarcinoma2017.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Omer Koc, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, Pharm D, BCOP

EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

TamoxifenMastalgia, severe2017.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

OxaliplatinNeuroblastoma, high-risk, relapsed/refractory (pediatrics)2017.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Nick Link, PharmD, BCOP

Heidi Trinkman, PharmD

EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Cladribine T-cell large granular lymphocytic leukemia (refractory)2017.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Polly Kintzel, PharmD, BCOP, BCPS

Jordan Lundberg, PharmD, BCOP
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AlemtuzumabMycosis fungoides/Sezary syndrome (advanced)2018.01Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Jordan Lundberg, PharmD, BCOP

Nick Link, PharmD, BCOP
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

AlemtuzumabT-cell large granular lymphocytic leukemia2018.01Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Jordan Lundberg, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

NilotinibAcute lymphoblastic leukemia, Ph+2018.01Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Heidi Trinkman, PharmD
EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

StreptozocinGastrointestinal neuroendocrine tumors2018.02Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP Polly

Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Jordan Lundberg, PharmD, BCOP
EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

TrastuzumabBreast cancer, metastatic, HER2-positive, hormone receptor-positive (in combination with an aromatase inhibitor)2018.03Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP
StrongA, GFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

LenvatinibHepatocellular carcinoma (advanced)2018.03 (updated from 2017.11)Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD
StrongAFor the updated LOE /Strength of Recommendation: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RuxolitinibGraft versus host disease (acute or chronic; treatment)2018.04Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Heidi Trinkman, PharmD
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

FilgrastimAlcoholic hepatitis (severe)2018.05Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

Jordan Lundberg, PharmD, BCOP
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

PrednisoneMultiple myeloma (previously untreated; transplant ineligible)2018.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Jordan Lundberg, PharmD, BCOP
StrongAFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

EverolimusHodgkin lymphoma (relapsed or refractory) 2018.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Omer Koc, MD

Nick Link, PharmD, BCOP

Jordan Lundberg, PharmD, BCOP
EquivocalCFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

EverolimusThymoma and thymic carcinomas (advanced, refractory) 2018.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP
EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

CetuximabPenile cancer (squamous cell, advanced or metastatic)2018.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Elizabeth Connor, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
EquivocalCFor the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

MethylprednisoloneProstate cancer (metastatic, castration-resistant)2018.07Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP

Jordan Lundberg, PharmD, BCOP
EquivocalBFor the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Off-Label Uses Removed From Database

Monograph Off-Label Use Removed Date Participating Panel Member(s) Strength of Recommendation Off-Label Use Removal Vote Record Conflict of Interest Statement
Ixabepilone Endometrial cancer (second-line treatment) 2014.11 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD, BCOP

Mark Holdsworth, PharmD
Against off-label use: Evidence suggests a lack of support for this off-label use; additional studies are needed to further define the role of ixabepilone in the management of this condition Remove the Off-Label Use: 4 of 5 (add to unsupported use) No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Bevacizumab Ovarian cancer, advanced, recurrent (platinum sensitive) 2014.11 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA-approved (no panel vote needed - removed from off-label uses due to approval by FDA) N/A N/A
Alemtuzumab Multiple sclerosis 2014.11 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA-approved (no panel vote needed - removed from off-label uses due to approval by FDA) N/A N/A
Medroxyprogesterone injection Renal Carcinoma (labeled use, add to Use: Unsupported) 2015.02 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Cater, MD

Omer Koc, MD

Polly Kintzel, PharmD, BCOP, BCPS
Against Off-Label Use Add to Use: Unsupported: 5 of 5 (add to unsupported use) No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Decitabine Sickle Cell Anemia 2015.05 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Heidi Trinkman, PharmD
Against off-label use: Evidence suggests a lack of support for this off-label use; evidence-based guidelines do not mention decitabine as a therapeutic option for management of sickle cell anemia. Additional studies are needed to further define the role of decitabine in the management of this condition. Remove the Off-Label Use: 4 of 5 (add to unsupported use)No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Topotecan Merkel cell carcinoma 2015.06 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP

Against off-label use: Limited evidence exists for the use of topotecan in the management of merkel cell carcinoma; additional trials are needed to further define the role of topotecan in the treatment of this condition. Remove the Off-Label Use: 5 of 5 (add to unsupported use) No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Octreotide Meningioma2015.09 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD
Add to Use: Unsupported: While results from a small study of octreotide LAR for recurrent meningioma demonstrated partial response or stable disease in some patients, subsequent studies in recurrent/progressive meningioma have not demonstrated a benefit. Given the unknown natural history of meningioma, the role of somatostatin analogues in meningioma is unclear.For the Use: 3 of 6 (Off-label use not added [no consensus]); Add to Use: UnsupportedNo Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest
PegfilgrastimPrevention of chemotherapy-induced neutropenia in children 2015.12 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed - removed from off-label uses due to pediatric dosing addition to FDA labeling).n/a n/a
Nivolumab Renal cell cancer, clear cell (advanced)2015.12 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/an/a
Nivolumab Melanoma, unresectable or metastatic (without BRAF mutation), first-line, single-agent therapy2015.12 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/an/a
Uridine Triacetate Fluorouracil overdose/overexposure2015.12 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/an/a
DocetaxelCervical Cancer (recurrent)2016.02 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Omer Koc, MD

Polly Kintzel, PharmD, BCOP, BCPS
Against off-label use: Evidence suggests a lack of support for this off-label use; additional studies are needed to further define the role of docetaxel in the management of this condition.Remove the off-label use: 3 of 5 (Add to Use: Unsupported) No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

PalbociclibBreast cancer, advanced (second-line endocrine-based therapy)2016.03 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/an/a
FulvestrantBreast cancer, advanced (second-line endocrine-based therapy)2016.02 Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA). n/an/a
CabozantinibRenal cell carcinoma, advanced2016.05 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/an/a
IfosfamideHead and neck cancer2016.09 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
Against off-label use: Evidence suggests a lack of support for this off-label use; other contemporary therapies have replaced the use of ifosfamide for the treatment of head and neck cancer.Remove the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

IfosfamideSmall cell lung cancer2016.09 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Corey Carter, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
Against off-label use: Evidence suggests a lack of support for this off-label use; other contemporary therapies have replaced the use of ifosfamide for the treatment of small cell lung cancer.Remove the off-label use: 5 of 5 (Add to Use: Unsupported) No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

NivolumabHead and neck cancer, squamous cell (recurrent or metastatic)2016.11 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/an/a
MitomycinNon-small cell lung cancer2016.11 Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP
Against off-label use: Evidence suggests a lack of support for this off-label use; other contemporary therapies have replaced the use of mitomycin for the treatment of non-small cell lung cancer.Remove the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

FluorouracilThymic cancers2017.01Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Mark Holdsworth, PharmD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD. BCOP
Against off-label use: A lack of evidence suggests a lack of support for this off-label use.Remove the off-label use: 5 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

Antithymocyte globulin (rabbit;Thymoglobulin)Myelodysplastic syndrome (low risk; non-sideroblastic)2017.05Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Corey Carter, MD

Polly Kintzel, PharmD, BCOP, BCPS

Nick Link, PharmD. BCOP
Against off-label use: A lack of evidence for antithymocyte globulin (rabbit; Thymoglobulin) suggests a lack of support for this off-label use.Remove the off-label use: 4 of 5 No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

No conflict of interest

RegorafenibHepatocellular carcinoma (intermediate or advanced)2017.05Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/a n/a
PembrolizumabUrothelial carcinoma (advanced)2017.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/a n/a
DabrafenibNon-small cell lung cancer, metastatic, relapsed or refractory (with BRAF V600E mutation)2017.07Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/a n/a
TrametinibNon-small cell lung cancer, metastatic, relapsed or refractory (with BRAF V600E mutation)2017.07Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/a n/a
TocilizumabCytokine release syndrome (due to CAR-T cell therapy)2017.09Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/a n/a
VemurafenibErdheim-Chester disease, refractory (with BRAF V600E mutation)2017.11Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved (no panel vote needed - removed from off-label uses due to approval by FDA).n/a n/a
Busulfan (oral)Chronic myeloid leukemia (palliative treatment)2017.12Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Heidi Trinkman, PharmD
Against the use: Although palliative treatment of chromic myeloid leukemia (CML) is as an approved use in the manufacturer’s labeling for busulfan tablets, other contemporary therapies have replaced the use of oral busulfan for management of CML. According to the European LeukemiaNet Recommendations for Management of CML, treatments include tyrosine kinase inhibitors, omacetaxine, or allogeneic transplant, however, oral busulfan (unless part of a transplant conditioning regimen) is not recommended (Baccarani 2013).Remove the off-label use: 4 of 5No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest
CladribineChronic myeloid leukemia (palliative treatment)2017.12Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Omer Koc, MD

Polly Kintzel, PharmD, BCOP, BCPS

Jordan Lundberg, PharmD, BCOP
Against off-label use: Evidence suggests a lack of support for this off-label use; other contemporary therapies have replaced the use of cladribine for the treatment of chronic lymphocytic leukemia.Remove the off-label use: 5 of 5No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest
OlaparibBreast cancer, metastatic, HER2-negative, BRCA-mutated2018.01Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/an/a
AbirateroneProstate cancer, metastatic or high-risk locally advanced, castration-sensitive2018.02Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/an/a
DurvalumabNon-small cell lung cancer (unresectable, locally advanced)2018.03Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/an/a
SargramostimHematopoietic radiation injury syndrome, acute2018.04Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved (no panel vote needed – removed from off-label uses due to approval by FDA).n/an/a
EstramustineProstate cancer (metastatic castration-resistant)2018.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP

Polly Kintzel, PharmD, BCOP, BCPS

Omer Koc, MD

Nick Link, PharmD, BCOP
While estramustine is approved for palliative treatment of progressive or metastatic prostate cancer, guidelines from the American Society of Clinical Oncology/ Cancer Care Ontario (for systemic therapy in men w/metastatic castration-resistant prostate cancer) recommend against offering estramustine to men with metastatic castration-resistant prostate cancer due to a lack of benefit in survival or quality of life and an increased risk of toxicity (ASCO [Basch 2014]).Remove the use: 5 of 5No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest
RituximabPemphigus vulgaris (newly diagnosed)2018.06Diedra Bragalone, PharmD, BCOP, BCPS

Stephanie Minich, PharmD, BCOP
FDA approved; (no panel vote needed – removed from off-label uses due to FDA approval) n/an/a
CetuximabNSCLC, EGFR-expressing, advanced2018.07Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Elizabeth Connor, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
American Society of Clinical Oncology (ASCO) guidelines for Systemic Therapy for Stage IV Non-Small Cell Lung Cancer do not recommend cetuximab in the treatment of advanced NSCLC (ASCO [Masters 2015]). Cetuximab does not currently have an established role in the treatment of NSCLC either as a component of initial therapy or as second-line therapy.Remove the off-label use: 5 of 5No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest
VinblastineBreast cancer2018.07Stephanie Minich, PharmD, BCOP

Diedra Bragalone, PharmD, BCOP, BCPS

Elizabeth Connor, MD

Omer Koc, MD

Nick Link, PharmD, BCOP
Although included in the manufacturer's labeling as a use, other contemporary therapies have replaced the use of vinblastine for the treatment of refractory breast cancer.Remove the use: 5 of 5No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

No Conflict of Interest

Last update August 1, 2018.